Novel Migraine Treatment Shows Mixed Results in Phase 3 Efficacy Trial
November 16th 2022Investigational migraine drug produces significant effects on both freedom-from-pain and MBS-free endpoints at 3 hours post administration and at additional efficacy measurement timepoints of 4, 6, 12, 24 and 48 hours.
Read More
Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
November 14th 2022Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Read More